Global sales for the cervical and lumbar disc replacement devices were $23.4 million, according to a news release. Resources associated with the discs will be allocated to “more profitable growth opportunities.”
Orthofix will still fulfill requirements related to post-market surveillance activities and completion of an Investigational Device Exemption study in the U.S.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
